Gestala raises $21.7M angel for China's first ultrasound BCI — chronic pain single session 50% reduction
Summary
Chengdu-based Gestala raised $21.7M (150M RMB) in an angel round co-led by Guosheng Capital and Dalton Venture, with Tsing Song Capital, Gobi Partners, Fourier Intelligence, and Seas Capital. Co-founded by NeuroXess co-founder Phoenix Peng, Gestala is developing China's first ultrasound-based bidirectional BCI targeting chronic pain, depression, Alzheimer's, Parkinson's, stroke, and epilepsy. Early clinical data showed 50% pain reduction per session lasting 1-2 weeks. Targets NMPA filing by end of 2026.
Why it matters
A $21.7M angel round — the stage before seed — for an ultrasound BCI startup at Gestala's level of technical ambition reflects extraordinary early investor conviction. With NeuroXess co-founder at the helm, Gestala inherits both the technical expertise and the clinical network needed to move quickly through NMPA's now-proven BCI regulatory pathway.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial